Plain-English translation of NCT04025762 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Type 1 diabetes research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial studied a new automated closed-loop insulin delivery system called CamAPS FX in older adults with type 1 diabetes. The system used a smartphone app connected to an insulin pump and glucose sensor to automatically deliver insulin day and night, adjusting doses based on real-time blood sugar readings. Researchers compared this automated approach to standard sensor-augmented insulin pump therapy to see which one helped people maintain better blood sugar control and had fewer low blood sugar events.
Managing type 1 diabetes becomes more complex with age, and older adults often struggle to keep their blood sugar in a safe range. This trial was designed to see whether this new treatment could make blood sugar management easier and safer for seniors, since no one had specifically tested this technology in adults aged 60 and older before.
Participants received 4 to 6 weeks of training, then took part in two separate 4-month periods testing each system in their own home under free-living conditions. During the study, participants wore the insulin pump, glucose sensor, and smartphone running the automated system (or used standard pump therapy during the comparison period), and they received 24/7 telephone support from the research team. Participants also attended regular clinic visits, performed blood sugar checks as instructed, and uploaded their pump and sensor data at regular intervals.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
United Kingdom